ALZHEIMER’S DISEASE - ETIOPATHOGENESIS, CLINICAL PRESENTATION, AND CURRENT DIAGNOSTIC METHODS - A LITERATURE REVIEW
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.5857Keywords:
Alzheimer's Disease, Neurodegeneration, Beta-Amyloid, Tau Protein, Neuroimaging, Cerebrospinal FluidAbstract
Introduction: Alzheimer’s disease (AD) is the most common cause of dementia, accounting for 60–80% of cases, and its prevalence is increasing as the population ages. It is estimated that approximately 50 million people worldwide currently live with dementia, and this number could triple by 2050. AD is a chronic, progressive, and incurable disease leading to significant disability and high healthcare costs. Neuropathologically, it is characterized by the presence of β-amyloid plaques and tau neurofibrillary tangles.
Aim of the study: The aim of this study was to present the current state of knowledge regarding Alzheimer’s disease, with particular emphasis on etiopathogenesis, risk factors, clinical symptoms, diagnostic methods, and modern biomarkers.
Material and methods: This is a review study based on an analysis of the current scientific literature on AD. The literature available in the PubMed and Google Scholar databases was analyzed using keywords.
Results and conclusions: A review of the literature indicates that AD is a disease with a complex pathogenesis involving β-amyloid accumulation, tau protein hyperphosphorylation, autophagy dysfunction, and genetic factors such as the APOE ε4 allele. Early symptoms mainly include memory and cognitive impairments. Biomarkers, including Aβ42/40, p-tau, NfL, and GFAP, as well as neuroimaging techniques such as MRI and PET, are of key importance in diagnosis. Early detection of the disease in the preclinical phase offers the possibility of implementing measures to slow its progression. Despite the lack of effective causal treatment, the development of biomarkers and diagnostic methods offers hope for improved early diagnosis and more effective monitoring of the disease’s progression.
References
Stefaniak, O., Dobrzyńska, M., Drzymała-Czyż, S., & Przysławski, J. (2022). Diet in the prevention of Alzheimer's disease: Current knowledge and future research requirements. Nutrients, 14(21), 4564. https://doi.org/10.3390/nu14214564
Twarowski, B., & Herbet, M. (2023). Inflammatory processes in Alzheimer's disease-pathomechanism, diagnosis and treatment: A review. International Journal of Molecular Sciences, 24(7), 6518. https://doi.org/10.3390/ijms24076518
Breijyeh, Z., & Karaman, R. (2020). Comprehensive review on Alzheimer’s disease: Causes and treatment. Molecules, 25(24), 5789. https://doi.org/10.3390/molecules25245789
Zhang, X. X., Tian, Y., Wang, Z. T., Ma, Y. H., Tan, L., & Yu, J. T. (2021). The epidemiology of Alzheimer's disease modifiable risk factors and prevention. The Journal of Prevention of Alzheimer's Disease, 8(3), 313–321. https://doi.org/10.14283/jpad.2021.15
Wong, W. (2020). Economic burden of alzheimer disease and managed care considerations. The American Journal of Managed Care, 26(8 Suppl), S177–S183. https://doi.org/10.37765/ajmc.2020.88482
Wilson, D. M., III, Cookson, M. R., Van Den Bosch, L., Zetterberg, H., Holtzman, D. M., & Dewachter, I. (2023). Hallmarks of neurodegenerative diseases. Cell, 186(4), 693–714. https://doi.org/10.1016/j.cell.2022.12.032
Orobets, K. S., & Karamyshev, A. L. (2023). Amyloid precursor protein and Alzheimer's disease. International Journal of Molecular Sciences, 24(19), 14794. https://doi.org/10.3390/ijms241914794
Ma, C., Hong, F., & Yang, S. (2022). Amyloidosis in Alzheimer's disease: Pathogeny, etiology, and related therapeutic directions. Molecules (Basel, Switzerland), 27(4), 1210. https://doi.org/10.3390/molecules27041210
Moloney, C. M., Lowe, V. J., & Murray, M. E. (2021). Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 17(9), 1554–1574. https://doi.org/10.1002/alz.12321
Kamatham, P. T., Shukla, R., Khatri, D. K., & Vora, L. K. (2024). Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier. Ageing Research Reviews, 101, 102481. https://doi.org/10.1016/j.arr.2024.102481
Wu, S., Wei, Y., Li, J., Bai, Y., Yin, P., & Wang, S. (2021). SIRT5 represses neurotrophic pathways and Aβ production in Alzheimer's disease by targeting autophagy. ACS Chemical Neuroscience, 12(23), 4428–4437. https://doi.org/10.1021/acschemneuro.1c00468
Jia, J., Xu, J., Liu, J., Wang, Y., Wang, Y., Cao, Y., Guo, Q., Qu, Q., Wei, C., Wei, W., Zhang, J., & Yu, E. (2021). Comprehensive management of daily living activities, behavioral and psychological symptoms, and cognitive function in patients with Alzheimer's disease: A Chinese consensus on the comprehensive management of Alzheimer's disease. Neuroscience Bulletin, 37(7), 1025–1038. https://doi.org/10.1007/s12264-021-00701-z
Jessen, F., Amariglio, R. E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chételat, G., Dubois, B., Dufouil, C., Ellis, K. A., van der Flier, W. M., Glodzik, L., van Harten, A. C., de Leon, M. J., McHugh, P., Mielke, M. M., Molinuevo, J. L., Mosconi, L., Osorio, R. S., Perrotin, A., … Subjective Cognitive Decline Initiative (SCD-I) Working Group (2014). A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 10(6), 844–852. https://doi.org/10.1016/j.jalz.2014.01.001
Prasad, S., Katta, M. R., Abhishek, S., Sridhar, R., Valisekka, S. S., Hameed, M., Kaur, J., & Walia, N. (2023). Recent advances in Lewy body dementia: A comprehensive review. Disease-a-Month: DM, 69(5), 101441. https://doi.org/10.1016/j.disamonth.2022.101441
Gordon, B. A., Blazey, T. M., Su, Y., Hari-Raj, A., Dincer, A., Flores, S., Christensen, J., McDade, E., Wang, G., Xiong, C., Cairns, N. J., Hassenstab, J., Marcus, D. S., Fagan, A. M., Jack, C. R., Jr., Hornbeck, R. C., Paumier, K. L., Ances, B. M., Berman, S. B., … Benzinger, T. L. S. (2018). Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: A longitudinal study. The Lancet Neurology, 17(3), 241–250. https://doi.org/10.1016/S1474-4422(18)30028-0
Chen, Y., Al-Nusaif, M., Li, S., Tan, X., Yang, H., Cai, H., & Le, W. (2024). Progress on early diagnosing Alzheimer's disease. Frontiers of Medicine, 18(3), 446–464. https://doi.org/10.1007/s11684-023-1047-1
Daou, L., El Alayli, A., Constantinos, F., Dib, G., & Barakat, M. (2023). Can neurocognitive assessment be a lower-cost substitute for biomarkers in predicting progression from mild cognitive impairment (MCI) to Alzheimer’s disease (AD)? a narrative review. Biomarkers in Neuropsychiatry, 9, 100069. https://doi.org/10.1016/j.bionps.2023.100069
Nunkoo, V. S., Jurcau, A., Les, M., Cristian, A., Militaru, M., Marge, C., Iovanovici, D. C., & Jurcau, M. C. (2025). Circulating biomarkers for the early diagnosis of Alzheimer's disease. International Journal of Molecular Sciences, 26(15), 7268. https://doi.org/10.3390/ijms26157268
Varesi, A., Carrara, A., Pires, V. G., Floris, V., Pierella, E., Savioli, G., Prasad, S., Esposito, C., Ricevuti, G., Chirumbolo, S., & Pascale, A. (2022). Blood-based biomarkers for Alzheimer's disease diagnosis and progression: An overview. Cells, 11(8), 1367. https://doi.org/10.3390/cells11081367
Jack, C. R., Jr., Andrews, S. J., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., Molinuevo, J. L., Okonkwo, O. C., Pani, L., Rafii, M. S., Scheltens, P., Siemers, E., Snyder, H. M., Sperling, R., Teunissen, C. E., & Carrillo, M. C. (2024). Revised criteria for the diagnosis and staging of Alzheimer's disease. Nature Medicine, 30(8), 2121–2124. https://doi.org/10.1038/s41591-024-02988-7
Lista, S., Mapstone, M., Caraci, F., et al. (2024). A critical appraisal of blood-based biomarkers for Alzheimer’s disease. Ageing Research Reviews, 96, 102290. https://doi.org/10.1016/j.arr.2024.102290
Andersen, E., Casteigne, B., Chapman, W. D., Creed, A., Foster, F., Lapins, A., Shatz, R., & Sawyer, R. P. (2021). Diagnostic biomarkers in Alzheimer’s disease. Biomarkers in Neuropsychiatry, 5, 100041. https://doi.org/10.1016/j.bionps.2021.100041
Guo, Y., Huang, Y. Y., Shen, X. N., Chen, S. D., Hu, H., Wang, Z. T., Tan, L., Yu, J. T., & Alzheimer’s Disease Neuroimaging Initiative (2021). Characterization of Alzheimer's tau biomarker discordance using plasma, CSF, and PET. Alzheimer's Research & Therapy, 13(1), 93. https://doi.org/10.1186/s13195-021-00834-3
Zetterberg, H., & Blennow, K. (2020). Blood biomarkers: Democratizing Alzheimer's diagnostics. Neuron, 106(6), 881–883. https://doi.org/10.1016/j.neuron.2020.06.004
Horie, K., Salvadó, G., Barthélemy, N. R., Janelidze, S., Li, Y., He, Y., Saef, B., Chen, C. D., Jiang, H., Strandberg, O., Pichet Binette, A., Palmqvist, S., Sato, C., Sachdev, P., Koyama, A., Gordon, B. A., Benzinger, T. L. S., Holtzman, D. M., Morris, J. C., … Bateman, R. J. (2023). CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease. Nature Medicine, 29(8), 1954–1963. https://doi.org/10.1038/s41591-023-02443-z
Furtner, J., & Prayer, D. (2021). Neuroimaging in dementia. Bildgebung in der Demenzdiagnostik. Wiener Medizinische Wochenschrift (1946), 171(11-12), 274–281. https://doi.org/10.1007/s10354-021-00825-x
Frisoni, G. B., Bocchetta, M., Chételat, G., Rabinovici, G. D., de Leon, M. J., Kaye, J., Reiman, E. M., Scheltens, P., Barkhof, F., Black, S. E., Brooks, D. J., Carrillo, M. C., Fox, N. C., Herholz, K., Nordberg, A., Jack, C. R., Jr., Jagust, W. J., Johnson, K. A., Rowe, C. C., … ISTAART's NeuroImaging Professional Interest Area (2013). Imaging markers for alzheimer disease: Which vs how. Neurology, 81(5), 487–500. https://doi.org/10.1212/WNL.0b013e31829d86e8
Crișan, G., Moldovean-Cioroianu, N. S., Timaru, D. G., Andrieș, G., Căinap, C., & Chiș, V. (2022). Radiopharmaceuticals for PET and SPECT imaging: A literature review over the last decade. International Journal of Molecular Sciences, 23(9), 5023. https://doi.org/10.3390/ijms23095023
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Mateusz Cieciora, Małgorzata Kawiorska, Julia Surowiec, Aleksandra Cieciora, Katarzyna Zegadło, Katarzyna Kuc, Maciej Dobrucki, Krzysztof Brzezicki, Patryk Jakubiak, Wiktoria Bełcikowska-Skowron
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
